Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To register, simply click the Register button at the top right.
Yes it's part of the selection criteria. Note however that they aren't only measuring levels, which Scheibenbogen aka Celltrend do, but also measure the functionality of them by essentially applying them to rats (spontaneously beating neonatal rat cardiomyocytes=naturally beating rat heart cells) and seeing whether that has an effect on these rats. Whether that's a good notion of functionality that carries over to humans is hard to asses, at least for me, but it's different to just measuring the levels which seems slightly useless.I'm still wondering if it really only works for those who have auto antibodies against G receptors and if that was a selection criteria?
Wow, this is very encouraging news. Thank you for posting, @tcamde.First patients are being treated now as part of the clincial trial. I know of 3 patients that have received the treatments/placebo. 2 had no effect (maybe placebo or treatment not working) and one has improved dramatically and interestingly keeps getting even better over time.
Nobody reported side effects.
One of the 3 accounts writing these reports doesn't have Long-Covid in the first place. So either it's a troll account or somethings gone wrong in selecting participants. It’s a double blinded trial with a follow-up period of 330 days. So I wouldn’t expect the participants to know in which arm they belong anytime before that (entire duration is 381 days).
We can probably figure out whether it's the same people.Possibly not, but I believe we're talking about the same people. One of the 3 people I'm talking about is https://twitter.com/SirchMarina reporting to be in the trial and writing about it (her tweets even include some rather authentic details, see for instance www.twitter.com/SirchMarina/status/1653006620174024704, www.twitter.com/SirchMarina/status/1684937498475053056). This person has previously been very open about having Post-Vac, see for instance www.twitter.com/SirchMarina/status/1641438259548139520, www.twitter.com/SirchMarina/status/1636266499609448448.
I don't know anything about the other people (Ingo or who else still exists).
Well, I agree that at least one person claiming to be in the trial should not be in the trial, but nonetheless, the one improving may be a legitimate LC patient.Unfortunately I have been able to confirm it. Marina Sirch is one of the 3 people that are commonly referred to on Facebook, WhatsApp and Twitter to be part of the trial. She is not the one improving, but that is irrelevant. The problem is that we already have people partcipating in this trial that knowingly don't have Long-Covid, which doesn't speak for the quality of the secltion criteria of trial or the honesty of the participants.
Yes, that is true. In the best case scenario this person isn't part of the trial (which seems less likely based on current information). The second best case scenario is that this person received a placebo. The worst case scenario is that this person received BC007 without having Long-Covid and having had Post-Vac for much longer than a year.Well, I agree that at least one person claiming to be in the trial should not be in the trial, but nonetheless, the one improving may be a legitimate LC patient.
For your "best case scenario": if this person wasn't in the trial, then they couldn't have received the BC007, correct? How is that the "best case scenario"?Yes, that is true. In the best case scenario this person isn't part of the trial (which seems less likely based on current information). The second best case scenario is that this person received a placebo. The worst case scenario is that this person received BC007 without having Long-Covid and having had Post-Vac for much longer than a year.
I'm talking about the person that doesn't have Long-Covid and claims to be part of the trial but hasn't improved. Does that make sense to you?For your "best case scenario": if this person wasn't in the trial, then they couldn't have received the BC007, correct? How is that the "best case scenario"?
For your "second best case scenario", if they got placebo, that would be worse news for patients than if they were in the BC007 arm, no? Again, I'm not following your logic here.
Your "worst case scenario" is admittedly worse than if they are a legit LC patient, but it still would suggest LC007 has positive effects for patients with related conditions.
Either I'm missing something here or you are grasping at straws, my friend.